ATRC:NSD-AtriCure Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 30.5

Change

-0.01 (-0.03)%

Market Cap

USD 1.67B

Volume

0.12M

Analyst Target

USD 55.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

+9.80 (+1.86%)

USD 192.19B
COO The Cooper Companies, Inc. Com..

+0.29 (+0.31%)

USD 18.65B
ALGN Align Technology Inc

+5.93 (+2.86%)

USD 17.86B
HOLX Hologic Inc

+0.18 (+0.25%)

USD 17.14B
RGEN Repligen Corporation

+1.30 (+0.89%)

USD 8.36B
MMSI Merit Medical Systems Inc

+0.47 (+0.48%)

USD 6.15B
ICUI ICU Medical Inc

+2.19 (+1.42%)

USD 3.97B
XRAY Dentsply Sirona Inc

-0.05 (-0.26%)

USD 3.92B
LMAT LeMaitre Vascular Inc

+1.25 (+1.37%)

USD 2.27B
AZTA Azenta Inc

+0.22 (+0.44%)

USD 2.08B

ETFs Containing ATRC

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.54% 60% D- 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.54% 60% D- 35% F
Trailing 12 Months  
Capital Gain -18.25% 52% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.25% 52% F 33% F
Trailing 5 Years  
Capital Gain -5.10% 63% D 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.10% 63% D 41% F
Average Annual (5 Year Horizon)  
Capital Gain 1.74% 42% F 43% F
Dividend Return 1.74% 42% F 39% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.45% 58% F 39% F
Risk Adjusted Return 3.60% 44% F 36% F
Market Capitalization 1.67B 74% C 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector